These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 10937803)

  • 1. Effects of the glycoprotein IIb/IIIa receptor antagonist c7E3 Fab and anticoagulants on platelet aggregation and thrombin potential under high coagulant challenge in vitro.
    Koestenberger M; Gallistl S; Cvirn G; Roschitz B; Muntean W
    Blood Coagul Fibrinolysis; 2000 Jul; 11(5):425-32. PubMed ID: 10937803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A laboratory method for parallel determination of platelet aggregation and thrombin generation.
    Köstenberger M; Gallistl S; Cvirn G; Muntean W
    Clin Lab; 2004; 50(1-2):41-8. PubMed ID: 15000219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention.
    Day JR; Malik IS; Weerasinghe A; Poullis M; Nadra I; Haskard DO; Taylor KM; Landis RC
    Heart; 2004 Jul; 90(7):794-9. PubMed ID: 15201252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The glycoprotein IIb/IIIa antagonist c7E3 inhibits platelet aggregation in the presence of heparin-associated antibodies.
    Liem TK; Teel R; Shukla S; Silver D
    J Vasc Surg; 1997 Jan; 25(1):124-30. PubMed ID: 9013915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.
    Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD
    Am Heart J; 2003 Feb; 145(2):e6. PubMed ID: 12595861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined effects of eptifibatide and anticoagulants: differences between LMWH and UH or rH in thrombin generation inhibition but not in platelet aggregation inhibition.
    Koestenberger M; Gallistl S; Cvirn G; Roschitz B; Petritsch M; Leschnik B; Muntean W
    Thromb Haemost; 2002 Dec; 88(6):1012-9. PubMed ID: 12529753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes.
    Li Y; Spencer FA; Ball S; Becker RC
    J Thromb Thrombolysis; 2000 Aug; 10(1):69-76. PubMed ID: 10947916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time.
    Ammar T; Scudder LE; Coller BS
    Circulation; 1997 Feb; 95(3):614-7. PubMed ID: 9024148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab.
    Mascelli MA; Kleiman NS; Marciniak SJ; Damaraju L; Weisman HF; Jordan RE
    Am Heart J; 2000 Apr; 139(4):696-703. PubMed ID: 10740154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
    Judge HM; Buckland RJ; Holgate CE; Storey RF
    Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.
    Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Pieper K; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD
    Am Heart J; 2001 Nov; 142(5):790-8. PubMed ID: 11685164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects.
    Klinkhardt U; Graff J; Westrup D; Kirchmaier CM; Esslinger HU; Breddin HK; Harder S
    Br J Clin Pharmacol; 2001 Sep; 52(3):297-305. PubMed ID: 11560562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.
    Mascelli MA; Worley S; Veriabo NJ; Lance ET; Mack S; Schaible T; Weisman HF; Jordan RE
    Circulation; 1997 Dec; 96(11):3860-6. PubMed ID: 9403608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
    Marciniak SJ; Jordan RE; Mascelli MA
    Thromb Haemost; 2001 Mar; 85(3):539-43. PubMed ID: 11307828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab.
    Dangas G; Badimon JJ; Coller BS; Fallon JT; Sharma SK; Hayes RM; Meraj P; Ambrose JA; Marmur JD
    Arterioscler Thromb Vasc Biol; 1998 Aug; 18(8):1342-9. PubMed ID: 9714143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention.
    Dangas G; Marmur JD; King TE; De Leon J; Sharma SK; Vidhun R; Feldman D; Stoynov MY; Badimon JJ; Ambrose JA
    Am Heart J; 1999 Jul; 138(1 Pt 1):49-54. PubMed ID: 10385763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abciximab inhibits procoagulant activity but not the release reaction upon collagen- or clot-adherent platelets.
    Ilveskero S; Lassila R
    J Thromb Haemost; 2003 Apr; 1(4):805-13. PubMed ID: 12871419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa.
    Turner NA; Moake JL; Kamat SG; Schafer AI; Kleiman NS; Jordan R; McIntire LV
    Circulation; 1995 Mar; 91(5):1354-62. PubMed ID: 7867173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevating local concentrations of GPIIb-IIIa antagonists counteracts platelet thrombus stability.
    Speich HE; Furman RR; Lands LT; Moodie GD; Jennings LK
    J Thromb Thrombolysis; 2013 Jul; 36(1):31-41. PubMed ID: 23073747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.